Company: GMRE
Filing Date: 2025-11-13
Form Type: 424B5
Source: 0001104659-25-110926
Chunk: 42

Company: Global Medical REIT Inc.
Filing Date: 2025-11-13
Form: 424B5
Chunk 42
---
 our stockholders or otherwise be in their best interests.

Restrictions on Ownership and Transfer

In order to ensure that we remain qualified as
a REIT for U.S. federal income tax purposes, among other purposes, our charter, including the Articles Supplementary, provides that generally
no person, other than certain exempted holders, may own, or be deemed to own by virtue of the attribution provisions of the Code, more
than 9.8% in value or in number of shares, whichever is more restrictive, of the outstanding shares of any class or series of our stock.
These provisions may restrict the ability of a holder of Series B Preferred Stock to convert such stock into our common stock as
described above under “— Conversion Rights.” The Board of Directors may, in its sole discretion, exempt a person from
the 9.8% ownership limit under certain circumstances as described under “Restrictions on Ownership and Transfer” in the accompanying
prospectus.

The beneficial ownership and/or constructive ownership
rules under the Code are complex and may cause shares of stock owned actually or constructively by a group of related individuals
and/or entities to be owned constructively by one individual or entity. See “Description of Capital Stock — Restrictions on
Ownership and Transfer” in the accompanying prospectus.

Listing

We intend to apply to list the Series B Preferred
Stock on the NYSE under the symbol “GMRE PrB.” If the listing application is approved, we expect trading of the Series B
Preferred Stock to commence within 30 days after initial delivery of the shares.

Transfer Agent, Registrar and Depositary

Equiniti Trust Company, LLC will be the transfer
agent, registrar, dividend disbursing agent, redemption agent and depositary for the Series B Preferred Stock.

<div align='center'>S-24

UNDERWRITING</div>

Raymond James, BMO and Stifel (the “Representatives”)
are acting as representatives of the underwriters named below. Subject to the terms and conditions stated in the underwriting agreement,
dated the date of this prospectus supplement, each underwriter named below has severally agreed to purchase, and we have agreed to sell
to that underwriter, the number of shares of Series B Preferred Stock set forth opposite the underwriter’s name.

| Underwriters                             |     | Number of 
 Shares    |
| Raymond James & Associates, Inc.         |     |           |
| BMO Capital Markets Corp.                |     |           |
| St